1 / 7

CTI Life Sciences Fund Introduction

CTI Life Sciences Fund Introduction. January 2008. CTI Life Sciences Fund - Raison D'être.

imogene-hicks
Download Presentation

CTI Life Sciences Fund Introduction

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CTI Life Sciences Fund Introduction January 2008

  2. CTI Life Sciences Fund - Raison D'être "Where broad Operational and VC experience come together to create and realize shareholder value in Canadian Life Sciences Companies with pre-clinical and clinical drugs, drug enabling technologies and medical devices”.

  3. CTI Life Sciences Fund – People Jean-François Leprince -Managing Partner Accomplished leader with 30 years of multi-products, multifunctional, multi-geographical experience in the pharmaceutical industry Richard Meadows-Managing Partner VC experience in two multi-billion dollar private equity funds along with 15+ years Business Development experience in the pharmaceutical industry Ken Pastor General Partner’s Representative 20 years experience in the financial market Shermaine Tilley – Principal 20 years experience in the biotech industry, including investment management, consulting, tech transfer and strong academic experience

  4. CTI Life Sciences Fund - Investment Objectives DRUGS, DRUG ENABLING TECHNOLOGIES, MEDICAL DEVICES CRITICAL SUCCESS FACTORS Scientific Innovation Entrepreneurship/ Leadership Partnering with U.S. VC’s Interacting with Big Pharmas/ Biotechs Positioning for Exits • Strategic objectives • Value Creation through Pre-clinical/POC Process • M&A Exits Financial objectives High Returns Goal: Achieve IRR’s commensurate with ability to execute strategy

  5. Ph III to market (NDA) Size of round: $25-50M Pre-Money $50-100M+ Post-Money: $75-150M Bump Up: ≈ 3-5 x Size of round: $1-5M Pre-Money $5-10M Post-Money: $6-15 M Size of round: $5-15M Pre-Money $10-20M Post-Money: $15-35M Bump Up: ≈ 2-3 x CTI Life Sciences Fund - Investment StrategyPicking the "right" Value Inflection Points

  6. CTI Life Sciences Fund Portfolio Companies Lead/Co-Lead Active Follower

  7. CTI Life Sciences Fund Overview • Emphasis on Quebec & Canadian life sciences companies, U.S. market opportunistically. • A highly experienced investment team. • A unique pro-active exit strategy • Through active post investment management. • Leveraging relationships with top advisors and US VC investors to position companies for successful exits. • M&A’s vs. I.P.O’s. • First Close: CAD $71 million, June 20 2006. • Target size: CAD $100 million, Achieved March 1 2007

More Related